Emergent BioSolutions (NYSE:EBS – Get Free Report) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Friday. Several other equities ...

LONDON, GREATER LONDON, UNITED KINGDOM, January 25, 2025 /EINPresswire / -- The ebanga market size has seen significant historical compound annual growth, growing from millions in 2024 to a higher ...

Papa presented the company’s “turnaround plan” for 2025 at J.P. Morgan. “We are focused on first stabilising the company, ...

Emergent BioSolutions (NYSE:EBS – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have ...

H.C. Wainwright & Co. reaffirmed its Buy rating and $15.00 price target for Emergent BioSolutions stock (NYSE:EBS). The ...

In the assessment of 12-month price targets, analysts unveil insights for Emergent BioSolutions, presenting an average target ...

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Emergent Biosolutions (EBS – Research Report), with a ...

What is Biodefense?Biodefense Market refers to strategies and technologies designed to protect populations from biological threats, including bioterrorism and accidental biological exposures. The use ...

Kaseya said the mpox vaccine has been well received in countries that have deployed the vaccine, including in the DRC. He ...

It will start by evaluating the safety and efficacy of brincidofovir. Brincidofovir is an antiviral from the global life sciences company Emergent BioSolutions. In the United States it is available ...

Africa CDC’s support for the MOSA, a pan-African randomized platform adaptive trial for the MpOx Study, adding to the initial EU funding, has ...

The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.